Neflamapimod Significantly Lowers Plasma GFAP and Correlates with Clinical Benefit in Dementia with Lewy Bodies: Results from the RewinD-LB Trial

neflamapimod (VX-745) - CervoMed

John J ALAM 1; Hui-May CHU 2; Amanda GARDNER 3; Blackburn KELLY 3; Charlotte E TEUNISSEN 4

Dec 14, 2025